AGAaron Goldberg

Aaron Goldberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aaron Goldberg has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Does recommending healthy diets in general practice benefit secondary prevention of cardiovascular disease? A systematic review and meta-analysis

    by Aaron Goldberg, Wasiq Sajjad, Linda Oude Griep, Esther Cruijsen

    Background: Suboptimal diet is the main preventable risk factor globally for cardiovascular disease (CVD), posing major burden for primary care. However, healthy dietary recommendations’ evidence in patients with established CVD is unclear. Aim: Systematically review and meta-analyse dietary patterns’ effect on CVD patients’ all-cause and CVD mortality, and CVD recurrence. Method: Publication databases were searched for randomised controlled trials (RCTs) (≥6 months follow-up) and prospective cohort studies. Random-effects meta-analysis calculated relative-risks (RR) and 95% confidence-intervals (95% CI). Cochrane bias risk tools assessed study quality. Results: Screening 28 291 abstracts identified 41 articles meeting inclusion criteria. Nineteen articles from 14 unique RCTs conducted 1956–2020, enrolling 14 065 CVD patients, compared fat-replacement, Mediterranean, low-fat, low-sodium, and high-fibre diets with minimal/no dietary advice. Pooled results showed no diet intervention significantly impacted mortality/CVD outcomes. However, stratified meta-analysis revealed a Mediterranean-diet significantly reduced CVD mortality (RR: 0.40; 95% CI: 0.19, 0.83). Twenty-two cohort studies, conducted 1976–2017 for 104 386 CVD patients, predominantly assessed a Mediterranean diet (60%), showing greatest healthy dietary pattern adherence significantly reduced all-cause mortality by 29% (0.71; 0.65, 0.78), CVD mortality by 25% (0.75; 0.66, 0.84), and CVD recurrence by 17% (0.83; 0.75, 0.92). Overall, there was considerable between-study heterogeneity (RCTs: I 2 = 34–60%, cohorts: I 2 = 49–76%) partly explained by disparate geographical locations, and studies were mainly classified as of some concerns (65% RCTs) or high bias risk (52% cohorts). Conclusion: GPs providing healthy dietary advice, particularly the Mediterranean diet, likely enhances CVD secondary prevention. However, cogent studies with clearly defined diets are required to bolster the evidence.

  • Open Access

    Improving Bone Protection Provision for Patients with Fragility Fractures

    by Aaron Goldberg

    Osteoporosis therapy is a crucial component of fragility fracture patients’ care. A Quality Improvement Project (QIP) was undertaken to review and improve such bone protection practice within a busy UK hospital orthopaedic department. Full-loop audit cycles, totalling 216 patients, were conducted before and after the implementation of a single-page checklist. This intervention significantly increased consultant-led osteoporosis plans by 37%, enhanced bone-sparing treatment administration by 20%, and eliminated unsafe prescriptions. Provision timeliness was not affected, but the communication of correct discharge information was significantly improved by 27%, and staff surveys showed the checklist was well-received, easy-to-use, and educational. Hopefully this will encourage other orthogeriatric teams to utilise a similarly effective and simple QI strategy.

  • Open Access

    How Close Are We to Patient-Side Troponin Testing?

    by Aaron Goldberg, Samuel McGrath, Michael Marber

    Laboratory-based high-sensitivity cardiac troponin testing has been the pillar for emergency stratification of suspected acute coronary syndrome for well over a decade. Point-of-care troponin assays achieving the requisite analytical sensitivity have recently been developed and could accelerate such assessment. This review summarises the latest assays and describes their potential diverse clinical utility in the emergency department, community healthcare, pre-hospital, and other hospital settings. It outlines the current clinical data but also highlights the evidence gap, particularly the need for clinical trials using whole blood, that must be addressed for safe and successful implementation of point-of-care troponin analysis into daily practice. Additionally, how point-of-care troponin testing can be coupled with advances in biosensor technology, cardiovascular screening, and triage algorithms is discussed.